Guangdong Taiantang Pharmaceutical Co., Ltd.

SZSE:002433.SZ

2.69 (CNY) • At close October 26, 2023
Overview | Financials

Numbers are in millions (except for per share data and ratios) CNY.

20232022202120202019201820172016201520142013201220112010200920082007
Revenue 410.361724.8452,264.1753,581.9494,013.1553,315.2983,238.9413,075.4452,371.6481,227.637785.166517.877417.367314.035288.335243.776182.971
Cost of Revenue 341.196442.4641,734.9682,650.2913,033.412,394.6512,269.6572,245.1261,697.114768.353460.658279.486240.315189.297176.325149.572113.826
Gross Profit 69.165282.381529.207931.657979.745920.646969.284830.32674.533459.284324.508238.39177.053124.739112.0194.20569.146
Gross Profit Ratio 0.1690.390.2340.260.2440.2780.2990.270.2840.3740.4130.460.4240.3970.3880.3860.378
Reseach & Development Expenses 7.47326.71730.420.38124.26122.9130.00420.43621.6227.222.9580.7710.4380.208000
General & Administrative Expenses 36.65334.36737.22349.85445.30139.91233.71537.71530.36516.09512.17313.44410.3177.43711.91814.09613.1
Selling & Marketing Expenses 217.557117.703369.193549.272511.016446.2350.703334.463295.898131.12193.2451.0559.94140.46428.9629.65718.086
SG&A 254.211152.07406.416599.126556.318486.113384.418372.178326.263147.216105.41364.49570.25847.940.87743.75331.186
Other Expenses -71.583140.316180.186165.221152.002-0.88149.86629.2843.1674.2493.4999.8781.3382.7225.9850.7150.39
Operating Expenses 427.694319.103617.003784.728732.581666.833553.301501.742443.979222.619155.013106.25191.88860.29342.91945.49332.511
Operating Income -2,213.852-68.887-87.796184.954278.413329.47304.333266.12219.119203.538153.052102.66884.8163.64464.70546.46235.193
Operating Income Ratio -5.395-0.095-0.0390.0520.0690.0990.0940.0870.0920.1660.1950.1980.2030.2030.2240.1910.192
Total Other Income Expenses Net -1,906.996-751.43-754.43-146.911-154.29974.776-61.784-33.43-8.447-28.88-13.012-20.1882.382.556-2.061-1.535-1.052
Income Before Tax -2,285.435-820.317-842.22638.044124.115328.59354.199295.148222.108207.786156.483111.95287.54467.00167.0347.17735.583
Income Before Tax Ratio -5.569-1.132-0.3720.0110.0310.0990.1090.0960.0940.1690.1990.2160.210.2130.2320.1940.194
Income Tax Expense 9.31633.259-10.30411.15522.2953.40959.88542.26826.5315.4119.18821.46913.39210.55213.1857.6655.222
Net Income -2,210.087-853.575-831.92122.22696.094270.892290.399243.328190.124186.307132.89788.05474.15356.44953.89138.28530.705
Net Income Ratio -5.386-1.178-0.3670.0060.0240.0820.090.0790.080.1520.1690.170.1780.180.1870.1570.168
EPS -2.88-1.11-1.080.0290.130.350.380.320.260.30.240.220.190.160.180.130.12
EPS Diluted -2.88-1.11-1.080.0290.130.350.320.310.260.30.240.220.190.160.180.130.12
EBITDA -312.92658.863-0.261291.083374.037603.524542.316414.811291.835297.16214.854168.144106.82478.2875.89752.63743.845
EBITDA Ratio -0.7630.081-00.0810.0930.1820.1670.1350.1230.2420.2740.3250.2560.2490.2630.2160.24